Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula

The market should treat this as a mix-shift story more than a unit-growth story. In infant nutrition, brand trust and on-shelf availability matter more than messaging, so the incremental upside to ABT is likely from trading consumers up into a higher-convenience format and defending share against Reckitt’s Enfamil rather than from expanding the category outright. If the new SKU stays near powder economics, the real financial lever is margin: ready-to-feed typically supports better gross profit per ounce if utilization is high, but that upside disappears quickly if the launch is used to cover limited production or retailer discounts.

The second-order effect is competitive pressure on premium formula branding. A whole-milk, sterile liquid format narrows a product attribute gap that smaller brands and private label cannot easily replicate because trust, sterile processing, and retailer placement are the true moats. That said, the launch may simply cannibalize ABT’s existing Similac liquid line, so the near-term P&L read-through could be modest unless scanner data shows net share gains versus Enfamil and store brands over the next 1-3 months.

The contrarian view is that investors may overrate the importance of a press-release product launch in a category with slow trial, high stickiness, and heavy regulatory scrutiny. The key falsifier is not the announcement but retail velocity: if ACV-adjusted sell-through, repeat purchase, or gross margin expansion does not show up in the next two quarters, this is noise. Longer term, any supply-chain hiccup or recall would reverse the narrative quickly because formula buyers punish reliability failures more than they reward formulation upgrades.